A Study of Treatment With NeoRecormon (Epoetin Beta) in Patients With Chronic Renal Anemia
Launched by HOFFMANN-LA ROCHE · May 3, 2006
Trial Information
Current as of June 29, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • adult patients \>=18 years of age;
- • chronic renal anemia;
- • not receiving renal replacement therapy.
- Exclusion Criteria:
- • women who are pregnant or lactating;
- • previous treatment with erythropoietin or other erythropoietic substance;
- • blood transfusion within the last 3 months;
- • need for dialysis expected in the next 6 months;
- • administration of another investigational drug within 30 days preceding study start, or during the study.
About Hoffmann La Roche
Hoffmann-La Roche, commonly known as Roche, is a global leader in biotechnology and pharmaceuticals, committed to advancing healthcare through innovative research and development. With a strong focus on oncology, immunology, infectious diseases, and central nervous system disorders, Roche leverages cutting-edge science to deliver transformative therapies and diagnostics. The company is dedicated to improving patient outcomes by conducting rigorous clinical trials and collaborating with healthcare professionals and organizations worldwide. Roche's unwavering commitment to precision medicine and personalized healthcare positions it at the forefront of the industry, driving progress in the quest for effective treatments and improved patient care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
St Pölten, , Austria
Berlin, , Germany
Bologna, , Italy
Napoli, , Italy
Madrid, , Spain
Belfast, , United Kingdom
Hong Kong, , Hong Kong
Valencia, , Spain
Boras, , Sweden
Stockholm, , Sweden
Taoyuan, , Taiwan
Istanbul, , Turkey
Izmir, , Turkey
Southampton, , United Kingdom
Parma, , Italy
Bordeaux, , France
Pavia, , Italy
Barcelona, , Spain
Gdansk, , Poland
Krakow, , Poland
Wroclaw, , Poland
London, , United Kingdom
Lyon, , France
Newcastle Upon Tyne, , United Kingdom
Bruxelles, , Belgium
Vandoeuvre Les Nancy, , France
Taipei, , Taiwan
Bangkok, , Thailand
Ostrava, , Czech Republic
Herlev, , Denmark
Colmar, , France
Oslo, , Norway
Karlstad, , Sweden
Roma, , Italy
Moscow, , Russian Federation
St Petersburg, , Russian Federation
Chiang Mai, , Thailand
Lecco, , Italy
Edegem, , Belgium
Tampere, , Finland
Boulogne, , France
Cuernavaca, , Mexico
Kielce, , Poland
Taichung, , Taiwan
Roskilde, , Denmark
Montpellier, , France
Villingen Schwenningen, , Germany
Paris, , France
Padova, , Italy
Carnaxide, , Portugal
Salford, , United Kingdom
Thessaloniki, , Greece
Ankara, , Turkey
Linz, , Austria
Dublin, , Ireland
Athens, , Greece
Amiens, , France
Jyväskylä, , Finland
Cagliari, , Italy
Olomouc, , Czech Republic
Porto, , Portugal
Brno, , Czech Republic
Havirov, , Czech Republic
Fredericia, , Denmark
Holbaek, , Denmark
Angouleme, , France
Saint Brieuc, , France
Troyes, , France
Würzburg, , Germany
Veria, , Greece
Busto Arsizio, , Italy
Cinisello Balsamo, , Italy
San Giovanni Rotondo, , Italy
Trieste, , Italy
Vimercate, , Italy
Tijuana, , Mexico
Almada, , Portugal
Lisboa, , Portugal
Las Palmas De Gran Canaria, , Spain
Helsingborg, , Sweden
Jonkoping, , Sweden
Norrkoping, , Sweden
Oerebro, , Sweden
Sundsvall, , Sweden
Tainan, , Taiwan
Surrey, , United Kingdom
Patients applied
Trial Officials
Clinical Trials
Study Chair
Hoffmann-La Roche
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials